뉴락시스NRXS 주가

NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum

Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]

NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y

NRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code.

Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges

Neuraxis Inc (NRXS) reports significant revenue growth and strategic expansions, while navigating insurance coverage hurdles and financial adjustments.

♻️ 재탕Transcript : NeurAxis, Inc., Q1 2026 Earnings Call, May 12, 2026

Presentation Operator MessageOperator Good day, and welcome to the NeurAxis First Quarter Fiscal Year 2026 Financial Results Conference Call. [Operator Instructions] Please note this event is being...

NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call May 12, 2026 9:00 AM EDTCompany ParticipantsBehnam Shamsian - Investor RelationsBrian Carrico - President, CEO...

NeurAxis (NRXS) Q1 2026 Revenue and EPS Beat Drive Record Revenue and Strong Pre-Market Gains

NeurAxis (NRXS) posted record Q1 2026 revenue of $1.61M, an 80% YoY surge, beating analyst estimates. Non-GAAP loss also narrowed, driving strong pre-market gains.

Neuraxis Reports Q1 2026 Results: Full Earnings Call Transcript

NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth

Conference call will be held today, Tuesday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter period ended March 31, 2026. 1Q26 Financial Highlights Revenues increased 80% year over year to $1.6M, reflecting the AMA Category I CPT®

Earnings Scheduled For May 12, 2026

Neuraxis Q1 EPS $(0.18) Beats $(0.19) Estimate, Sales $1.607M Beat $1.450M Estimate

Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 45.45 percent increase over losses of $(0.33) per share from the same